You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Biotechnology company Inscripta raises $125M in series D round
Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world
You Down With PPP? Consider The Risks
Street Talk Episode 60 - You Down With PPP? Consider The Risks
Street Talk Episode 56 - Latest bank MOE shows even the strong need scale to thrive
Inscripta Inc. raised $125 million in its series D funding round, which was led by Paladin Capital Group.
New investors JS Capital Management LLC and Oak HC/FT Partners LLC participated in the round, alongside existing investors.
Inscripta has now raised a total of $259.5 million.
Inscripta is a Boulder, Colo.-based biotechnology company that is developing a benchtop platform for genome-scale engineering.